Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 13/20 | 0.60 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.49 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.49 |
| ▸ | CPT1A | P50416 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2001670 | 0.90 | RORC (0.58) | RORCNR1H2NR1H3CPT1ACYP2C9 | |
| SCHEMBL2000444 | 0.89 | RORC (0.49) | RORCNR1H2NR1H3CPT1ACYP2C9 | |
| SCHEMBL2003367 | 0.89 | CPT1A (0.52) | RORCNR1H3CPT1ACYP2C9HTR6 | |
| SCHEMBL12569920 | 0.86 | RORC (0.57) | RORCNR1H2NR1H3CPT1ACYP2C9 | |
| SCHEMBL2001013 | 0.86 | RORC (0.51) | RORCCPT1ACYP2C9MEN1KMT2A | |
| SCHEMBL2002159 | 0.84 | RORC (0.53) | RORCNR1H2NR1H3CPT1ACYP2C9 | |
| SCHEMBL1999081 | 0.84 | RORC (0.57) | RORCNR1H2NR1H3CPT1ACYP2C9 | |
| SCHEMBL2006093 | 0.82 | CNR1 (0.59) | RORCNR1H2NR1H3CPT1AMEN1 | |
| SCHEMBL2001755 | 0.81 | RORC (0.55) | RORCNR1H2NR1H3CPT1ACYP2C9 | |
| SCHEMBL2002521 | 0.81 | RORC (0.55) | RORCNR1H2NR1H3CPT1ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960377-B2 | Substituted pyridoxazines | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20090247502-A1 | SUBSTITUTED PYRIDOXAZINES | CARA THERAPEUTICS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| WO-2009120660-A2 | SUBSTITUTED PYRIDOXAZINES | CARA THERAPEUTICS, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247502-A1 | SUBSTITUTED PYRIDOXAZINES | CNR1, CNR2, TRPV1 | RORC 122/4885NR1H2 208/4885NR1H3 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.